epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-118, Phase II. In start-up

Treatment-resistant major depressive disorder

FBK-118 against placebo in treatment-resistant major depressive disorder. Sponsor: Fabrikam Neuroscience (fictional), CNS and psychiatry.

Key risk indicators watch each site, as its data arrives, for the risks on this study's Risks tab under Design and risks. A problem shows at the site before it reaches the study's KPIs or QTLs.

Thresholds by country

A country's threshold is tighter than the default only where a sourced country risk supports it: one here. Everywhere else the default applies, because no difference between countries was found.

KRIDefaultUnited StatesUnited KingdomSpainPolandSites over
Site activation overdueDays a site's activation runs past the end of its country's planned start-up window Above 30 days0 daysDefaultDefaultDefault0 of 135
Screen failure above the study'sPercentage points by which a site's screen failure exceeds the study's own, once it has screened enough patients Above +15 pointsDefaultDefaultDefaultDefaultToo early
Data entry lagMedian days from a patient's visit to its data being entered, over the last three months Above 7 daysDefaultDefaultDefaultDefaultToo early
Queries open over 30 daysShare of a site's open data queries that have been open for more than 30 days, over the last three months Above 20%DefaultDefaultDefaultDefaultToo early
Important protocol deviationsImportant protocol deviations per hundred patient-months in the study at the site, so long and short studies compare fairly Above 2DefaultDefaultDefaultDefaultToo early
Consent findingsConsent findings (missing, outdated or incomplete consent records) per hundred patients consented at the site Above 5DefaultDefaultDefaultDefaultToo early
Study drug at the siteWeeks of study drug held at the site, resupplied early below the threshold Below 4 weeksDefaultDefaultDefaultDefaultNot in the data
Enrolment against the diversity planShare of the enrolment goal for each under-represented group met so far, against the study's diversity action plan Below 80%Default–––Not in the data
  • United States, site activation overdue: 0 days. US sites are activated slowly after the first: 309 days to activate 75% of US sites against 34 to 126 days elsewhere. A late US site is escalated at once. (register PM-03)

Sites over a threshold

No site is over a threshold.

Sources: epiClinical synthetic KRI data, in which levels follow each site's own facts (such as coordinator time), never its country. Readings marked too few wait until a site has enough patients; drug supply and diversity come from systems the synthetic data does not include.